Treatment selection in HIV Learning Zone
Antiretroviral therapies (ART) for human immunodeficiency virus (HIV) infection have been continuously evolving for the last 40 years1. Combination therapy with three antiretroviral agents (3DR) was the cornerstone of treatment; however, adverse effects associated with lifetime exposure to antiretroviral agents encouraged the development of two-drug regimens (2DR)1. Several clinical trials comparing 2DR and 3DR in treatment-naive and treatment-experienced patients showed the non-inferior efficacy of 2DR1. 2DR are now recommended in treatment guidelines and include the first long-acting antiretroviral regimen for the treatment of HIV1,2. 2DR have increased the pool of treatment options for people with HIV and their consulting health practitioners to explore.
The tolerability, safety, metabolic profiles and drug interactions of 2DR vary from 3DR and depending on the constituent drugs1
References
- Perez-Gonzalez A, Suarez-Garcia I, Ocampo A, Poveda E. Two-Drug Regimens for HIV-Current Evidence, Research Gaps and Future Challenges. Microorganisms. 2022;10(2).
- World Health Organization. HIV and AIDS. https://www.who.int/news-room/fact-sheets/detail/hiv-aids. Accessed 22 Aug 2023.
of interest
are looking at
saved
next event
Developed by EPG Health, for Medthority. This content has been developed in collaboration with the sponsor ViiV Healthcare and has been independently reviewed by an HIV specialist physician. EPG Health received funding from the sponsor to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.
Job code: NP-GBL-2DR-WCNT-230001
Date of preparation: November 2024